“Clinical studies indicate that cannabidiol (CBD), the primary nonaddictivecomponent of cannabis that interacts with the serotonin (5-HT)1A receptor, may possess analgesic and anxiolytic effects.
Cannabidiol (CBD), has recently been shown to possess considerable therapeutic potential for treating a wide range of disorders such as chronic pain, nausea, epilepsy, psychosis and anxiety.
Several preclinical studies have demonstrated the analgesic properties of CBD.
Clinical evidence showed the effectiveness of CBD to treat symptoms of neuropathic pain”

National Library of Medicine/NIH– ncbi.nlm.nih.gov/pmc/articles/PMC6319597/

Patient case reports are presented describing the use of cannabidiol (CBD) for the symptomatic relief of a lumbar compression fracture and in the mitigation of thoracic discomfort and dysesthesia secondary to a surgically resected meningioma. CBD appears to have antisnociceptive and anti-inflammatory effects on opioid-naive patients with neuro-pathic and radicular pain.

Conclusion: Hemp-derived CBD in a transdermal cream provided significant symptom and pain relief for the patients described in this case series

National Library of Medicine/NIH– pubmed.ncbi.nlm.nih.gov/32421842/

A 2001 study demonstrated that cannabinoid receptors are involved in the nervous system response linked to arthritis and concluded that “these novel targets may be advantageous for the treatment of inflammatory pain.” Research results suggest treatment with cannabinoids also effective for other types of inflammatory joint diseases such as gout. “JS had severe arthritis and fibromyalgia with constant pain in the knees. She started massaging CBD oil into her painful knees twice a day. In less than a week, she was nearly pain free.
“I can even go up and down steps and not be in agony,” she reported. “CBD works better than the prescription pain cream I was using! I feel like this product has given me my life back.”

Leinow, Leonard; Birnbaum, Juliana. CBD: A Patient’s Guide to Medicinal Cannabis (p. 105). North Atlantic Books

CBD is known agonist of serotonin 5-HT1A receptors (Russo et al., 2005) and transient receptor potential vanilloid type 1 (TRPV1) receptors (Bisogno et al., 2001).
It can also enhance adenosine receptor signaling by inhibiting adenosine inactivation, suggesting a potential therapeutic role in pain and inflammation (Carrier et al., 2006).
The antioxidant and anti-inflammatory properties of this compound may explain its potential neuroprotective actions (Scuderi et al., 2009).
Irrespective of the mechanism of action, there is evidence that CBD could potentially be exploited in the treatment and symptom relief of various neurological disorders such as epilepsy and seizures (Hofmann and Frazier, 2013; Jones et al., 2010), psychosis (Leweke et al., 2016), anxiety (Bergamaschi et al., 2011), movement disorders (e.g., Huntington’s disease and amyotrophic lateral sclerosis) (de Lago and Fernandez-Ruiz, 2007; Iuvone et al., 2009), and multiple sclerosis (Lakhan and Rowland, 2009).

National Center for Biotechnology Information – https://www.ncbi.nlm.nih.gov/books/NBK425762/